Compare HP & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HP | TVTX |
|---|---|---|
| Founded | 1920 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 1994 | 2013 |
| Metric | HP | TVTX |
|---|---|---|
| Price | $41.07 | $41.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $34.17 | ★ $40.62 |
| AVG Volume (30 Days) | 1.1M | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,746,013,000.00 | N/A |
| Revenue This Year | $9.50 | $44.76 |
| Revenue Next Year | $3.34 | $35.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 35.89 | N/A |
| 52 Week Low | $14.65 | $13.88 |
| 52 Week High | $41.78 | $48.61 |
| Indicator | HP | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.58 | 53.40 |
| Support Level | $32.88 | $41.55 |
| Resistance Level | $41.68 | $42.06 |
| Average True Range (ATR) | 1.51 | 2.34 |
| MACD | 0.08 | -0.57 |
| Stochastic Oscillator | 90.77 | 15.42 |
Helmerich & Payne Inc provides performance-driven drilling solutions and technologies to make hydrocarbon recovery safer and more economical for oil and gas exploration and production companies. Focusing on the drilling segment, its technology services develop and commercialize solutions that improve drilling efficiency, accuracy, and wellbore quality and placement. The company operates through North America Solutions, International Solutions, and Offshore Solutions segments. The North America segment runs a technologically advanced AC drive drilling rig fleet in the U.S., with a presence in shale and unconventional basins, while the Offshore Solutions segment, operating rigs on fixed-leg and floating platforms, generates the majority of revenue.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.